KRAS mutated endothelium promotes the occurrence and development of AVMs through a variety of ways, including promoting EndMT, angiogenesis, VEGF signaling pathway and pericyte loss. KRAS mutation in ...
Table 2. Modality of response/resistance to first-line VEGF/VEGFR inhibitors and possible second-line treatment options to be explored. Clinical response to first-line therapy Putative molecular ...
Shanghai Henlius Biotech, Inc. Class H ( ($HK:2696) ) has shared an update. Shanghai Henlius Biotech has initiated a first-in-human phase 1 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback